|
US4987071A
(en)
|
1986-12-03 |
1991-01-22 |
University Patents, Inc. |
RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
|
|
US5116742A
(en)
|
1986-12-03 |
1992-05-26 |
University Patents, Inc. |
RNA ribozyme restriction endoribonucleases and methods
|
|
AU630497B2
(en)
|
1989-09-05 |
1992-10-29 |
Immunex Corporation |
Tumor necrosis factor-alpha and -beta receptors
|
|
ZA929699B
(en)
|
1991-12-20 |
1994-06-14 |
Lilly Co Eli |
Sulfonimidamides
|
|
US5705398A
(en)
|
1994-03-02 |
1998-01-06 |
The Scripps Research Institute |
Methods for identifying inhibitors of LPS-mediated LBP binding
|
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
|
DK0929578T3
(da)
|
1996-02-09 |
2003-08-25 |
Abbott Lab Bermuda Ltd |
Humane antistoffer, der binder human TNFalfa
|
|
CA2329065A1
(en)
*
|
1998-05-05 |
1999-11-11 |
Francisco Xavier Talamas |
Pyrazole derivatives as p-38 map kinase inhibitors
|
|
KR101120857B1
(ko)
|
2003-06-26 |
2012-04-12 |
노파르티스 아게 |
5원의 헤테로사이클-기재 ｐ38 키나제 억제제
|
|
US20080280910A1
(en)
*
|
2007-03-22 |
2008-11-13 |
Keith Allan Menear |
Phthalazinone derivatives
|
|
US8884006B2
(en)
|
2011-09-19 |
2014-11-11 |
University Of Puerto Rico |
Small-molecule inhibitors of Rac1 in metastatic breast cancer
|
|
TW201439066A
(zh)
|
2012-11-30 |
2014-10-16 |
Kyowa Hakko Kirin Co Ltd |
含氮雜環化合物
|
|
ITMI20131658A1
(it)
|
2013-10-08 |
2015-04-09 |
Getters Spa |
Combinazione di materiali per dispositivi di rilascio di mercurio e dispositivi contenenti detta combinazione di materiali
|
|
US9714288B2
(en)
|
2014-09-30 |
2017-07-25 |
The Regents Of The University Of California |
Antisense compounds and uses thereof
|
|
SI3259253T1
(sl)
*
|
2015-02-16 |
2020-07-31 |
The University Of Queensland |
Sulfonilsečnine in sorodne spojine ter njihova uporaba
|
|
MX387515B
(es)
*
|
2015-10-29 |
2025-03-18 |
Merck Sharp & Dohme Llc |
Inhibidores de factor xia.
|
|
FR3046933B1
(fr)
*
|
2016-01-25 |
2018-03-02 |
Galderma Research & Development |
Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
|
|
US11339136B2
(en)
*
|
2016-04-18 |
2022-05-24 |
Novartis Ag |
Compounds and compositions for treating conditions associated with NLRP activity
|
|
US11447460B2
(en)
*
|
2016-04-18 |
2022-09-20 |
Novartis Ag |
Compounds and compositions for treating conditions associated with NLRP activity
|
|
CA3021349A1
(en)
|
2016-04-19 |
2017-10-26 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
|
JP6962941B2
(ja)
|
2016-06-14 |
2021-11-05 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Ａｐｊ受容体アゴニストとしての４−ヒドロキシ−３−スルホニルピリジン−２（１ｈ）−オン
|
|
EP3571187B1
(en)
|
2017-01-23 |
2023-11-22 |
Genentech, Inc. |
Chemical compounds as inhibitors of interleukin-1 activity
|
|
WO2018225018A1
(en)
|
2017-06-09 |
2018-12-13 |
Cadila Healthcare Limited |
Novel substituted sulfoximine compounds
|
|
ES2988798T3
(es)
|
2017-07-24 |
2024-11-21 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP
|
|
EP3668840A1
(en)
|
2017-08-15 |
2020-06-24 |
Inflazome Limited |
Novel sulfonamide carboxamide compounds
|
|
CA3105521A1
(en)
|
2018-07-20 |
2020-01-23 |
F. Hoffmann-La Roche Ag |
Sulfonimidamide compounds as inhibitors of interleukin-1 activity
|
|
GB201902327D0
(en)
|
2019-02-20 |
2019-04-03 |
Inflazome Ltd |
Novel compounds
|
|
BR112021003665A2
(pt)
|
2018-09-13 |
2021-05-18 |
Bayer Aktiengesellschaft |
derivados de heterocicleno como agentes de controle de pragas
|
|
EP3911323A4
(en)
|
2019-01-18 |
2022-11-16 |
Nuvation Bio Inc. |
HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
|
|
EP3986879B1
(en)
|
2019-06-21 |
2024-10-02 |
AC Immune SA |
Fused 1,2-thiazoles and 1,2-thiazines which act as nlrp3 modulators
|